Galbraithwichmann3589

Obstructive sleep apnoea (OSA) is associated with excessive daytime sleepiness and therefore affects traffic safety. The risk factors for OSA are age and BMI, and therefore sedentary occupational groups are likely to have a high prevalence of OSA. Our aim was to investigate the prevalence and identify the risk factors for OSA and Type 2 diabetes (T2D) among occupational truck drivers in Denmark.

Occupational truck drivers were recruited and their pulse oximetry and nasal respiratory flow were measured with the ApneaLink device. Androgen Receptor Antagonists The Apnea-Hypopnea Index (AHI), defined as the average number of apnoeas and hypopnoeas per hour of sleep, was used to classify 1) non OSA (AHI less-than 5/h), 2) mild OSA (5/h ≤ AHI less-than 15/h), 3) moderate OSA (15/h ≤ AHI ≤ 30/h) and 4) severe OSA (AHI > 30/h). Risk factors for OSA and T2D were investigated by linear and logistic regressions.

A total of 57 of 97 drivers were included in the analysis, all of whom were men, and 56% had OSA. The linear regressions showed all of the evaluated risk factors to be positively associated (less-than 0.01) with the AHI score, supported by the estimated odds ratios of having above-recommended levels of the evaluated risk factors when classified as having OSA.

All the evaluated risk factors were significantly associated with AHI, and the prevalence of OSA was above mean levels in the population. Confirmation of these results is warranted in future studies.

This study was supported by unrestricted grants from The FDE foundation, The Danish Council for Safe Traffic and Nordsjaellands Hospital.

none.

none.

Due to the coronavirus disease 2019 (COVID-19) exposure in Denmark, first-line referral centres were established to handle all patients suspected of COVID-19 or other upper respiratory tract infection. Here we report the first experiences from a first-line referral centre from Amager-Hvidovre Hospital, situated on the outskirts of Copenhagen.

A retrospective quality assessment was performed with collection of symptom patterns and COVID-19 status.

During the first 24 days, a total of 3,551 patients were referred for assessment of symptoms of upper respiratory tract infection and COVID-19. A total of 2,048 patients were assessed as having mild symptoms and referred for COVID-19 testing alone, whereas 337 patients were assessed clinically by a physician. Thirty-seven were positive for COVID-19 infection, 286 were negative. The most common symptoms reported were fever, coughing and dyspnoea. Fever was an independent predictor of COVID-19 infection (odds ratio (OR) = 2.25 (95% confidence interval (CI) 1.08-5.04); p = 0.037); whereas sore throat was not (OR = 0.40 (95% CI 0.15-0.92); p = 0.045). Only a small number of patients reported loss of taste or anosmia. In total, 113 patients were admitted to hospital, the majority of patients were discharged within 24 hours with mild symptoms of upper respiratory tract infections. Three of the COVID-19-positive patients developed a severe infection and two had a fatal outcome.

The present study is the first to report the experiences and symptom patterns of a COVID-19 first-line referral centre with efficient triage of patients in need of hospitalisation.

none.

not relevant.

not relevant.

5q spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by insufficient survival motor neuron protein. Untreated SMA involves death or permanent respiratory support (type 1), inability to walk (type 2) or ability to walk (type 3). The incidence of SMA is 1 in 7,500 live births, equivalant to eight children being born with SMA in Denmark annually.

We undertook a systematic review of the efficacy of nusinersen as SMA treatment. We included randomised controlled trials and cohort studies. Our primary endpoints were survival without permanent respiratory support and change in motor function.

We identified 658 articles and included 13 of these (two randomised controlled trials and 11 cohort studies). Nusinersen increased survival without permanent respiratory support in SMA type 1 and increased motor function development in types 1-3. Nusinersen treatment before symptom onset in children with presymptomatic SMA produced near-normal motor development. So far, nusinersen has only minor safety concerns mostly related to the lumbar puncture.

Nusinersen increased survival without permanent ventilatory support in children with SMA type 1. Improvements in SMA type 2 and 3 were less evident. Better outcomes were seen in young children with a short disease duration, particularly in children receiving nusinersen before symptom onset. Newborn SMA screening may facilitate presymptomatic treatment with splice modification (nusinersen, risdiplam) or gene implantation therapy (AVXS-101, zolgensma).

Nusinersen increased survival without permanent ventilatory support in children with SMA type 1. Improvements in SMA type 2 and 3 were less evident. Better outcomes were seen in young children with a short disease duration, particularly in children receiving nusinersen before symptom onset. Newborn SMA screening may facilitate presymptomatic treatment with splice modification (nusinersen, risdiplam) or gene implantation therapy (AVXS-101, zolgensma).

Tonsillectomy is one of the most common procedures in the field of ear, nose and throat procedures. In 2012, the annual incidence in Denmark was 129.4 per 100,000 inhabitants. A common complication is post-tonsillectomy haemorrhaging (PTH). The overall PTH rates vary widely among studies ranging from 0.5% to 33%.

This was a nationwide open-population, retrospective and registry-based cohort study in Danes who underwent tonsillectomy complicated by PTH in hospitals and private otorhinolaryngology (ORL) offices in the period from 1991 to 2012.

In the 1991-2012 period, a total of 177,211 tonsillectomies were performed among which 9,221 had a registered PTH (rPTH) (5.2%). The annual incidence rate of rPTH increased from 3% in 1991 to 13% in 2012 (p less-than 0.05). Males aged 20-40 years had a significantly higher risk of rPTH with the highest increase in rPTH incidence rates from 9.0% in 1998 to 16.4% in 2012 (p less-than 0.05). Approx. 12% had a primary rPTH within the first 24 hours; the maximum incidence of rPTH was on day six (14%).